RJA
TECX

Raymond James & Associates’s Tectonic Therapeutic TECX Stock Holding History

Raymond James & Associates’s Portfolio TECX Stock Details TECX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,240
Closed -$57K – 4293
2021
Q4 		$57K Sell
1,240
-26
-2% -$1.49K ﹤0.01% 3930
2021
Q3 		$85K Buy
+1,266
New +$104K ﹤0.01% 3860
2020
Q1 		– Sell
-944
Closed -$228K – 3749
2019
Q4 		$228K Hold
944
– – ﹤0.01% 3265
2019
Q3 		$160K Buy
+944
New +$214K ﹤0.01% 3324

Other funds holding TECX

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's TECX Position: Q1 2022 in Review

Raymond James & Associates sold out of Tectonic Therapeutic (TECX) in Q1 2022, closing a stake of 1,240 shares — an estimated $57K sold.

Raymond James & Associates first reported a position in TECX in Q3 2019 and held it in 4 quarters. The position peaked at $228K in Q4 2019. 79 funds tracked by Wall St. Rank hold TECX as of Q1 2022.

  • Raymond James & Associates reported no remaining Tectonic Therapeutic position as of Q1 2022 after selling out during the quarter.
  • Raymond James & Associates sold 1,240 Tectonic Therapeutic shares in Q1 2022, an estimated $57K.
  • Raymond James & Associates first reported a position in Tectonic Therapeutic in Q3 2019 and held it in 4 quarters.
  • Raymond James & Associates's Tectonic Therapeutic position peaked at $228K in Q4 2019.
  • 79 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q1 2022.

Based on Raymond James & Associates's 13F filing for Q1 2022, filed 11 May 2022.